COEUS and Emerging Therapy Solutions partner to advance value-based healthcare and commercial innovation.

January 10, 2023 – Devon, PA, and Bloomington, MN – COEUS, formerly COEUS Holdings, a leading healthcare communications, technology, talent, and consulting firm delivering a variety of services and platforms to all stakeholders in the healthcare ecosystem, today announced a strategic partnership with Emerging Therapy Solutions® (ETS), a company providing risk management and cost-containment solutions associated with high-cost therapies for rare and complex conditions to healthcare payers, including reinsurers for health plans and stop loss carriers for self-funded employers.

“As the pace quickens for the introduction and increased uptake of novel, high-cost treatments, the need to develop and leverage innovative solutions to inform the payor market of what to expect, and accurately track and report patient outcomes after therapy administration continues to heighten,” said David McLean, Chief Executive Officer of ETS. “By providing our payor clients a comprehensive suite of tools and services including our Centers of Excellence (COE) network management, actuarial forecasting tools, leading clinical content, and financial tracking and reporting capabilities, ETS has built relationships with our customers to help support appropriate access for these important life-saving therapies. Through this exciting partnership, ETS is now able to provide access to the value-based contracts utilizing the COEBRA™ Platform for management, allowing us to further enhance our cost-benefit modeling of these new therapies and help our clients adjust their financial exposure over time.”

The partnership will benefit both organizations by combining their innovative services in support of the healthcare industry’s movement towards aligning payments to a therapy’s derived value.

“Innovation in drug development continues to accelerate, providing personalized life-changing therapies to patients in need. That same level of innovation needs to be deployed commercially to ensure that these novel therapies can be paid for within a healthcare system that wasn’t designed to absorb many one-time, high-cost treatments. Long-term success in value-based pricing is contingent not only on accurately defining the right group of patients and analyzing a complete record of their health in order to predict and measure their outcomes, but also ensuring we can trace back payments to any entity that has paid for a given therapy over any number of years so they can recoup some of that cost if the therapy fails” said Marc Hixson, CEO of COEUS. “By partnering with ETS, we can leverage its client network of risk-bearing entities – ranging from first dollar payers to stop loss and reinsurance – for access to these agreements and to continue to pay for these innovative therapies while appropriately adjusting their financial risk or exposure.”

About the COEBRA™ Platform

The COEBRA™ Platform supports the collection and secure housing of data that allows disparate data sources to be combined and analyzed to better demonstrate total therapeutic impact on a patient’s illness. With today’s innovative and breakthrough medicines, there may not always be a clinical marker available to measure the value of the therapy. The COEBRA™ Platform offers a composite view of the therapeutic impact to both payers and manufacturers by incorporating metrics from claims data, electronic medical records, supply chain, patients and providers, and wearables.

About COEUS

Established in 2009, COEUS is a leading healthcare consulting, communications, technology, and talent firm. The company offers clients a variety of services, as well as SaaS technology platforms, for various stakeholders throughout the healthcare ecosystem including all payers and emerging or more established drug manufacturers. Leveraging the deep knowledge and experience of the company’s many subject matter experts, COEUS works on all drug types with a particular focus on cell and gene therapies, rare diseases, and oncology. The company also has unique expertise in the creation and management of value-based agreements by leveraging COEBRA™, the company’s evidence and outcomes adjudication platform. In its 13-year history, the company has supported the launch of more than 120 pharmaceutical brands and has worked with more than 300 pharma clients including many top global pharmaceutical manufacturers. To learn more about COEUS and the company’s offerings, visit 1coeus.com.

About Emerging Therapy Solutions

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans and self-funded employers manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies. To learn more about ETS and the company’s offerings, visit https://emergingtherapies.com.

COEUS Media Contact: 
Owen Murphy | 215.680.0155
omurphy@1coeus.com

ETS Media Contact:
Sara Hakanson | 612.839.1711
sara.hakanson@emergingtherapies.com